174 related articles for article (PubMed ID: 20402712)
1. Impact of obsessive-compulsive disorder on the antimanic response to olanzapine therapy in youth with bipolar disorder.
Joshi G; Mick E; Wozniak J; Geller D; Park J; Strauss S; Biederman J
Bipolar Disord; 2010 Mar; 12(2):196-204. PubMed ID: 20402712
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of comorbid obsessive-compulsive disorder and bipolar disorder in children and adolescents.
Joshi G; Wozniak J; Petty C; Vivas F; Yorks D; Biederman J; Geller D
Bipolar Disord; 2010 Mar; 12(2):185-95. PubMed ID: 20402711
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.
Houston JP; Tohen M; Degenhardt EK; Jamal HH; Liu LL; Ketter TA
J Clin Psychiatry; 2009 Nov; 70(11):1540-7. PubMed ID: 19778495
[TBL] [Abstract][Full Text] [Related]
4. Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial.
Sahraian A; Bigdeli M; Ghanizadeh A; Akhondzadeh S
J Affect Disord; 2014 Sep; 166():201-5. PubMed ID: 25012432
[TBL] [Abstract][Full Text] [Related]
5. Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole.
Wozniak J; DiSalvo M; Farrell A; Yule A; Joshi G; Cook E; Faraone SV; Biederman J
J Psychopharmacol; 2022 May; 36(5):637-644. PubMed ID: 35510655
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
[TBL] [Abstract][Full Text] [Related]
7. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study.
Marazziti D; Pfanner C; Dell'Osso B; Ciapparelli A; Presta S; Corretti G; Di Nasso E; Mungai F; Dell'Osso L
J Psychopharmacol; 2005 Jul; 19(4):392-4. PubMed ID: 15982994
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
Bogetto F; Bellino S; Vaschetto P; Ziero S
Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
[TBL] [Abstract][Full Text] [Related]
9. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression.
Keck PE; Corya SA; Altshuler LL; Ketter TA; McElroy SL; Case M; Briggs SD; Tohen M
J Clin Psychiatry; 2005 May; 66(5):611-6. PubMed ID: 15889948
[TBL] [Abstract][Full Text] [Related]
10. Response to second generation antipsychotics in youth with comorbid bipolar disorder and autism spectrum disorder.
Joshi G; Biederman J; Wozniak J; Doyle R; Hammerness P; Galdo M; Sullivan N; Williams C; Brethel K; Woodworth KY; Mick E
CNS Neurosci Ther; 2012 Jan; 18(1):28-33. PubMed ID: 21114638
[TBL] [Abstract][Full Text] [Related]
11. Impact of comorbid anxiety disorders and obsessive-compulsive disorder on 24-month clinical outcomes of bipolar I disorder.
Kim SW; Berk L; Kulkarni J; Dodd S; de Castella A; Fitzgerald PB; Amminger GP; Berk M
J Affect Disord; 2014 Sep; 166():243-8. PubMed ID: 25012437
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine vs. lithium in management of acute mania.
Shafti SS
J Affect Disord; 2010 May; 122(3):273-6. PubMed ID: 19740546
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Ringold AL; Elliott MA
J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole augmentation in treating comorbid bipolar disorder and obsessive-compulsive disorder: A systematic review.
Amerio A; Odone A; Ghaemi SN
J Affect Disord; 2019 Apr; 249():15-19. PubMed ID: 30743017
[TBL] [Abstract][Full Text] [Related]
15. Bipolar co-morbidity in pediatric obsessive-compulsive disorder: clinical and treatment implications.
Masi G; Perugi G; Millepiedi S; Toni C; Mucci M; Pfanner C; Berloffa S; Pari C; Akiskal HS
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):475-86. PubMed ID: 17822342
[TBL] [Abstract][Full Text] [Related]
16. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
17. Acute phase results from STORM, a multicountry observational study of bipolar disorder treatment and outcomes.
Treuer T; Oruc L; Loza N; El Saidi MA; Kovacs Z; Akkaya C; Gülseren S; Saylan M; Colman SA; Harrison GA
Psychiatr Danub; 2007 Dec; 19(4):282-95. PubMed ID: 18000479
[TBL] [Abstract][Full Text] [Related]
18. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?
Geller DA; Biederman J; Stewart SE; Mullin B; Farrell C; Wagner KD; Emslie G; Carpenter D
J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S19-29. PubMed ID: 12880497
[TBL] [Abstract][Full Text] [Related]
19. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder.
Wozniak J; Mick E; Waxmonsky J; Kotarski M; Hantsoo L; Biederman J
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):539-45. PubMed ID: 19877978
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
Weiss EL; Potenza MN; McDougle CJ; Epperson CN
J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
